Is that how Tonix Pharmaceuticals (TNXP) surged in the Premarket today?

DPRO Stock
DPRO Stock

Tonix Pharmaceuticals Holding Corp. (TNXP) shares go up more than 28% to $0.849 in the ‎premarket trading session after it revealed the closing of the purchase of a 44-acre site in ‎Hamilton, Montana, that will be used to develop and manufacture vaccines. In September ‎‎2020, Tonix entered into a lease agreement to purchase 40,000 square feet in ‎Massachusetts to house their new Advanced Development Center for accelerated testing of ‎vaccines for clinical trials.‎

Get the hottest stocks to trade ‎every day before the market opens 100% ‎free. Click here now. 

‎The Montana and Massachusetts facilities are also planned to promote the production and ‎manufacturing of candidate Tonix vaccines provided by adapted horsepox vaccines, TNX-‎‎1800, a possible COVID-19 vaccine, and TNX-801, a potential vaccine for smallpox and ‎monkeypox.‎

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Read More

Tonix Pharmaceuticals is currently working on COVID-19 vaccines using two live viral vector ‎platforms, horsepox and bovine parainfluenza virus (BPI virus). COVID-19 has four potential ‎vaccines in development based on the horsebox vector and two vaccines based on the BPI ‎vector. The Company’s lead vaccine, TNX-1800, is based on the horsepox vector1. The ‎horsepox virus is thought to be very similar to the smallpox vaccine, which was developed by ‎Dr. Edward Jenner and eradicated smallpox: the only disease ever destroyed. It was recently ‎discovered that horsepox is nearly identical to a vaccine used in the US in the mid-1800s for ‎smallpox2. TNX-1800 is believed to produce a predominantly T cell response to vaccination ‎and to prevent onward transmission. In the first quarter of 2021, Tonix plans to report ‎efficacy data from its animal challenge studies on TNX-1800.‎


Please enter your comment!
Please enter your name here